Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Malley
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Affinivax, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Malley co-founded Affinivax, the main mission of which is to develop novel vaccines using the MAPS technology developed by Dr. Malley’s laboratory. One of the main goals of the company is to ensure global access for any vaccine that the Company develops and may have applicability to the developing world. The purpose of the subject research is to optimize a TB MAPS vaccine.
As such, the outcome of the research has the potential to indirectly affect the Company in that it is conceivable that progress on this grant could enhance the view that the MAPS technology is indeed valuable. However, Affinivax does not have rights to use the MAPS technology in application to Tuberculosis and is not pursuing this area.
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine
Project Narrative The proposed research is highly relevant to public health because it proposes to optimize and further the development of a tuberculosis vaccine using a new vaccine strategy, the Multiple Antigen Presenting System (MAPS), based on strong preliminary data showing efficacy of the vaccine in a mouse model. At the completion of these studies, it is expected that we will have selected a vaccine development candidate, evaluated its efficacy in a highly relevant model of pulmonary tuberculosis, and begun process development of the vaccine.
Filed on January 08, 2018.
Tell us what you know about Richard Malley's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Richard Malley filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Malley | Boston Children's Hospital | Conflict of Interest | Affinivax, Inc. | $100,000 - $149,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.